Our Market Access experts investigate what early access opportunities are available in China to enab...
Read moreThe provision of funding for Early Access Programmes is not ubiquitous. We explore which EU5 countri...
Read moreAlmost a decade after it's inception, what have we learned from the UK early access to medicines sch...
Read moreOur experts provide an overview of the five key trends that could shape the pricing and market acces...
Read moreWe discuss gene therapy pricing and reimbursement, manufacturing methods, analytical analysis, and k...
Read moreOur market access experts cover the changes to the joint EU HTA process that occurred in 2022 and wh...
Read moreWe discuss the advantages and disadvantages of using international reference pricing for consistent ...
Read moreThe pricing dynamics of biosimilars, depends on the type of biosimilar, its indication and the chann...
Read moreThe short answer to the question “how important is HTA when launching a biosimilar in the EU5?” ...
Read moreIntroduction The European landscape has seen both approvals and withdrawals of cell and gene therapi...
Read more